Optieum Biotechnologies

The core of Optieum's operations is its proprietary CAR discovery engine, the Eumbody System. This platform diverges from conventional methods by focusing on the functional capabilities of T-cells rather than just binding affinity. It employs empirical methodologies and functional screening to identify and optimize CAR constructs, specifically the single-chain variable fragment (scFv) binding domains. The system is engineered to fine-tune the activation threshold of T-cells, which enhances their ability to proliferate, react to tumor profiles, and prevent antigen escape.

Optieum's therapeutic pipeline targets both hematological malignancies and solid tumors. A primary focus is on solid tumors, which have traditionally been challenging for CAR-T therapies. Its lead candidate, OPTF01, targets Fibroblast Activation Protein Alpha (FAPα), a protein found on cancer-associated fibroblasts (CAFs) that are crucial to the tumor microenvironment. This approach aims to disrupt the tumor's supportive structure while attacking the cancer cells directly. OPTF01 is currently advancing toward an Investigational New Drug (IND) filing with the U.S. FDA for treating glioblastoma, an aggressive brain cancer. The company has secured significant funding to advance this program, including a ¥1.33 billion Series A round in January 2025 and a grant of up to $39 million from the Japan Agency for Medical Research and Development (AMED). To support the manufacturing of its therapies, Optieum has entered into partnerships with Contract Development and Manufacturing Organizations (CDMOs) like Genezen and Cellipont Bioservices for the production of materials required for its clinical trials.